Scribd Logo
Upload

Welcome to Scribd!

  • 476 views

    DAPA HF Summary Slide

    Uploaded by

    Yerlis Ospino
    The DAPA-HF trial tested the SGLT2 inhibitor dapagliflozin versus placebo in patients with heart failure and reduced ejection fraction. Results showed the primary composite endpoint of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit occurred in 16.3% of patients on dapagliflozin compared to 21.2% of patients on placebo, representing a statistically significant reduction. Dapagliflozin also reduced rates of cardiovascular death and hospitalization for heart failure compared to placebo. The study authors concluded dapagliflozin was beneficial for patients with symptomatic heart failure due to reduced ejection fraction.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    DAPA HF Summary Slide

    Uploaded by

    Yerlis Ospino
    476 views1 page
    The DAPA-HF trial tested the SGLT2 inhibitor dapagliflozin versus placebo in patients with heart failure and reduced ejection fraction. Results showed the primary composite endpoint of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit occurred in 16.3% of patients on dapagliflozin compared to 21.2% of patients on placebo, representing a statistically significant reduction. Dapagliflozin also reduced rates of cardiovascular death and hospitalization for heart failure compared to placebo. The study authors concluded dapagliflozin was beneficial for patients with symptomatic heart failure due to reduced ejection fraction.

    Original Title

    DAPA-HF-Summary-Slide

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The DAPA-HF trial tested the SGLT2 inhibitor dapagliflozin versus placebo in patients with heart failure and reduced ejection fraction. Results showed the primary composite endpoint of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit occurred in 16.3% of patients on dapagliflozin compared to 21.2% of patients on placebo, representing a statistically significant reduction. Dapagliflozin also reduced rates of cardiovascular death and hospitalization for heart failure compared to placebo. The study authors concluded dapagliflozin was beneficial for patients with symptomatic heart failure due to reduced ejection fraction.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    476 views1 page

    DAPA HF Summary Slide

    Uploaded by

    Yerlis Ospino
    The DAPA-HF trial tested the SGLT2 inhibitor dapagliflozin versus placebo in patients with heart failure and reduced ejection fraction. Results showed the primary composite endpoint of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit occurred in 16.3% of patients on dapagliflozin compared to 21.2% of patients on placebo, representing a statistically significant reduction. Dapagliflozin also reduced rates of cardiovascular death and hospitalization for heart failure compared to placebo. The study authors concluded dapagliflozin was beneficial for patients with symptomatic heart failure due to reduced ejection fraction.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 1

    DAPA-HF

    #ESCCongress
    Trial Description: Patients with heart failure with reduced ejection fraction (irrespective of diabetes status) were randomized to
    dapagliflozin 10 mg daily vs. placebo.
    RESULTS
    (p < 0.001) • Primary efficacy endpoint: cardiovascular death, hospitalization for heart failure, or
    urgent heart failure visit occurred in 16.3% of the dapagliflozin group compared
    24 21.2 with 21.2% of the placebo group (p < 0.001)
    • Cardiovascular death: 9.6% with dapagliflozin vs. 11.5% with placebo
    16.3
    %

    • Hospitalization for heart failure: 9.7% with dapagliflozin vs. 13.4% with placebo
    12
    CONCLUSIONS
    • Among patients with symptomatic heart failure due to reduced left ventricular
    ejection fraction, dapagliflozin was beneficial
    • Dapagliflozin vs. placebo was associated with a reduction in cardiovascular deaths
    0
    1 and heart failure events
    Primary endpoint
    McMurray JJ, et al. N Engl J Med 2019;Sep 19:[Epub]
    Dapagliflozin Placebo
    (n = 2,373) (n = 2,371)

    You might also like

    pFad - Phonifier reborn

    Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

    Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


    Alternative Proxies:

    Alternative Proxy

    pFad Proxy

    pFad v3 Proxy

    pFad v4 Proxy